Eli Lilly and Rimidi to offer diabetes management solutions

18 December 2017 (Last Updated November 22nd, 2018 11:24)

Eli Lilly has entered a non-exclusive agreement with digital health firm Rimidi to develop provider-focused tools for delivering personalised diabetes management solutions.

Eli Lilly has entered a non-exclusive agreement with digital health firm Rimidi to develop provider-focused tools for delivering personalised diabetes management solutions.

The collaboration is intended to enable effective insulin usage and optimised diabetes management while maintaining normal clinical workflow.

The firms plan to combine Rimidi’s diabetes management software platform with Eli Lilly’s integrated insulin management system that is in the development phase.

Rimidi CEO Lucienne Ide said: “Diabetes management is a collaborative effort between people with diabetes and their healthcare providers.

“With the right support, they can achieve better results together.”

Rimidi’s platform utilises individual characteristics and clinical histories of diabetes patients to detect people who could benefit from a particular management technique.

“The integrated system is part of the firm’s Connected Diabetes Ecosystem that is being developed to facilitate effective insulin usage for easy diabetes management.”

The platform runs on top of select electronic medical records systems to provide smooth workflow experience for point of care clinicians.

Lilly’s insulin management system is being developed to combine a connected insulin pen, glucose-sensing technologies and software applications to offer personalised recommendations on insulin dose.

The integrated system is part of the firm’s Connected Diabetes Ecosystem that is being developed to facilitate effective insulin usage for easy diabetes management.

The Ecosystem also includes an automated insulin delivery system that is designed as a hybrid closed-loop platform to leverage connected devices for automated insulin dosing.

Both of the Lilly’s systems are currently undergoing clinical trials and are expected to be commercialised in the coming two to three years.